TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34872515

Group type: EXPERIMENTAL
Intervention: Standard anti-NTM treatment initiated within 3 months after diagnosis of NTM pulmonary disease
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: HRCT chest images findings in patients with NTM pulmonary disease
Number of subjects: 202

Group type: COMPARATOR
Intervention: HRCT chest images findings in patients without NTM pulmonary disease
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of HRCT features
Number of subjects: 202
Study: 34872549

Group type: EXPERIMENTAL
Intervention: Two-item swallowing screen (oral stereognosis and cough-reflex tests)
Number of subjects: 123
Study: 34872587

Group type: EXPERIMENTAL
Intervention: Low omega-3 PUFA intake group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High omega-3 PUFA intake group
Number of subjects: 62
Study: 34872604

Group type: EXPERIMENTAL
Intervention: DMSO-containing protocol (P1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DMSO-free protocol (P2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open vitrification system
Number of subjects: 12

Group type: COMPARATOR
Intervention: Closed vitrification system
Number of subjects: 12
Study: 34872617

Group type: EXPERIMENTAL
Intervention: intensive BP lowering to a target systolic BP of < 140 mmHg within 30 min
Number of subjects: 3116

Group type: COMPARATOR
Intervention: guideline-recommended BP management according to local protocols
Number of subjects: 3116
Study: 34872619

Group type: EXPERIMENTAL
Intervention: E3 webinar-based training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E3 webinar plus consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed training
Number of subjects: 0
Study: 34873004

Group type: EXPERIMENTAL
Intervention: Trial of labour offered to women with internal-os-distance >5 mm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Women with normally located placenta
Number of subjects: 30
Study: 34873092

Group type: EXPERIMENTAL
Intervention: Steatosis (n=30)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Fibrosis (n=22)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal (n=30)
Number of subjects: 82
Study: 34873185

Group type: EXPERIMENTAL
Intervention: Cognitive stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypercapnic stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short source-detector separation (SDS) channels during cognitive stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short source-detector separation (SDS) channels during hypercapnic stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very low frequency (VLF) band activity
Number of subjects: 0
Study: 34873221

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - biceps curl and squat training, 2 days/week, 60-70% repetition maximum, 3-4 sets, 120 s rest intervals, reps until muscular failure
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - biceps curl and squat training
Number of subjects: 18
Study: 34873345

Group type: EXPERIMENTAL
Intervention: Avapritinib, a selective KIT D816V inhibitor, starting dose of 200 mg once daily
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 62
Study: 34873347

Group type: EXPERIMENTAL
Intervention: Avapritinib (BLU-285) at doses of 30-400 mg once daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Avapritinib (BLU-285)
Number of subjects: 86
Study: 34873419

Group type: EXPERIMENTAL
Intervention: Mindful parenting workshop
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study: 34873795

Group type: EXPERIMENTAL
Intervention: CPAP telemonitoring
Number of subjects: 555
Study: 34873921

Group type: EXPERIMENTAL
Intervention: Standardized common carotid artery IMT
Number of subjects: 1309
Study: 34873975

Group type: EXPERIMENTAL
Intervention: Trilaciclib prior to chemotherapy
Number of subjects: 0
Study: 34874228

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) including modified GA (mGA) assessing comorbidities, medications, nutritional status, basic- and instrumental activities of daily living (IADL), mobility, falls, cognition, and depressive symptoms.
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Nutritional status and IADL function as assessed by mGA.
Number of subjects: 301
Study: 34874345

Group type: EXPERIMENTAL
Intervention: 360°-CZT camera
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional camera
Number of subjects: 92
Study: 34874404

Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 320

Group type: COMPARATOR
Intervention: Adult-led asthma self-management program (Control)
Number of subjects: 320
Study: 34874509

Group type: EXPERIMENTAL
Intervention: LA strain during conduit phase (LAScd)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: LA strain during reservoir phase (LASr)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: LAScd cutoff value of -11%
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 30-day cumulative risk of AF with LAScd > -11%
Number of subjects: 79
Study: 34874514

Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2247

Group type: EXPERIMENTAL
Intervention: Ubrogepant (50 mg and 100 mg) in long-term safety trial
Number of subjects: 2247
Study: 34874567

Group type: EXPERIMENTAL
Intervention: IgE-sensitization
Number of subjects: 0
Study: 34874751

Group type: EXPERIMENTAL
Intervention: Low-risk SCU HB
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intermediate-risk SCU HB
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-risk SCU HB
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-risk non-SCU HB
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intermediate-risk non-SCU HB
Number of subjects: 35

Group type: COMPARATOR
Intervention: High-risk non-SCU HB
Number of subjects: 35
Study: 34874836

Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 3164
Study: 34874888

Group type: EXPERIMENTAL
Intervention: blended cognitive behavioral therapy (bCBT)
Number of subjects: 240
Study: 34874892

Group type: EXPERIMENTAL
Intervention: Generic risk alert
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Enhanced education
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Building self-efficacy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Fostering motivation
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Improving self-regulation
Number of subjects: 159

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 159
Study: 34875023

Group type: EXPERIMENTAL
Intervention: AHSCT with lymphodepleting, reduced intensity regimen including CYC, fludarabine, and rituximab.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AHSCT with lymphodepleting, reduced intensity regimen.
Number of subjects: 8
Study: 34875086

Group type: EXPERIMENTAL
Intervention: Patients with primary social anxiety disorder or primary BDD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 30
Study: 34875106

Group type: COMPARATOR
Intervention: Antidepressant monotherapy
Number of subjects: 929

Group type: COMPARATOR
Intervention: Antipsychotic monotherapy
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Combination of antidepressant plus antipsychotic
Number of subjects: 929

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 929
Study: 34875107

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤2 years
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 25
Study: 34875111

Group type: EXPERIMENTAL
Intervention: High-dose thromboprophylaxis
Number of subjects: 165

Group type: COMPARATOR
Intervention: Intermediate-dose thromboprophylaxis
Number of subjects: 165
Study: 34875258

Group type: EXPERIMENTAL
Intervention: High-definition white-light imaging (HDWLI) + virtual chromoendoscopy (VCE)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Dye-based chromoendoscopy (DBC)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Absence of a demarcated area (DA)
Number of subjects: 400
Study: 34875458

Group type: EXPERIMENTAL
Intervention: SPACE-MS technique
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: SPACE-MS metrics (including anisotropy, planarity, sphericity, neuraxis caudality index)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Motor and cognitive disability scales assessments
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Structural brain MRI (1.5/3.0 T)
Number of subjects: 515
Study: 34875909

Group type: COMPARATOR
Intervention: Cluster 1 (optimal oral health and preserved masticatory capacity)
Number of subjects: 5294

Group type: EXPERIMENTAL
Intervention: Cluster 2 (moderate oral health and moderately impaired masticatory capacity)
Number of subjects: 5294

Group type: EXPERIMENTAL
Intervention: Cluster 3 (poor oral health and severely impaired masticatory capacity)
Number of subjects: 5294
Study: 34876196

Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard of Care (SOC) antibiotics
Number of subjects: 284
Study: 34876207

Group type: EXPERIMENTAL
Intervention: Propranolol (group 1) for patients with positive high-sensitive troponin T (HsTnT) status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (group 2) for patients with negative HsTnT status
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (group 3) for patients with negative HsTnT status
Number of subjects: 0
Study: 34876283

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (N = 84)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (N = 166)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 250
Study: 34876381

Group type: EXPERIMENTAL
Intervention: Plaque rupture
Number of subjects: 198
Study: 34876396

Group type: EXPERIMENTAL
Intervention: Cloud DX Vitaliti continuous vital signs monitor (CVSM) for continuous noninvasive blood pressure (cNIBP) measurements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cloud DX Vitaliti continuous vital signs monitor (CVSM)
Number of subjects: 20
Study: 34876408

Group type: EXPERIMENTAL
Intervention: CART therapy targeting BCMA, fractioned dose of 3×10
Number of subjects: 1
Study: 34876409

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg every 3 weeks
Number of subjects: 121
Study: 34876419

Group type: EXPERIMENTAL
Intervention: Isocaloric toddler milk with 1.5 g/100 kcal protein
Number of subjects: 1618

Group type: COMPARATOR
Intervention: Isocaloric toddler milk with 6.15 g/100 kcal protein (control)
Number of subjects: 1618
Study: 34876420

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin hydrochloride, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo capsule matching the active study drug, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Number of subjects: 634
Study: 34876429

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)-based mobile app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 34876434

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg ATG
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: ATG (0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg)
Number of subjects: 114
Study: 34876457

Group type: EXPERIMENTAL
Intervention: Improved Maternity Waiting Home (MWH) model
Number of subjects: 2381

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 2381
Study: 34876622

Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome patients with acute neurological disorders
Number of subjects: 2402

Group type: COMPARATOR
Intervention: Takotsubo syndrome patients without acute neurological disorders
Number of subjects: 2402
Study: 34877470

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-FMT treatment
Number of subjects: 17
Study: 34877629

Group type: EXPERIMENTAL
Intervention: CDSS-generated STOPP/START signals
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: STOPP signals
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: START signals
Number of subjects: 826

Group type: COMPARATOR
Intervention: STOPP signals in Ireland
Number of subjects: 826

Group type: COMPARATOR
Intervention: START signals in Ireland
Number of subjects: 826

Group type: COMPARATOR
Intervention: STOPP signals in the Netherlands
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: STOPP signals in surgical wards
Number of subjects: 826
Study: 34877761

Group type: EXPERIMENTAL
Intervention: HbA1c levels in healthy children
Number of subjects: 2455
Study: 34877828

Group type: EXPERIMENTAL
Intervention: High pre-/high post-PCI FFR group
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Low pre-/high post-PCI FFR group
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: High pre-/low post-PCI FFR group
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Low pre-/low post-PCI FFR group
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Low pre-PCI FFR group
Number of subjects: 1479

Group type: COMPARATOR
Intervention: High pre-PCI FFR group
Number of subjects: 1479
Study: 34877830

Group type: EXPERIMENTAL
Intervention: Axillary ultrasonography (US) for nodal evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized imaging protocol and criteria for evaluation of axillary lymph nodes
Number of subjects: 0
Study: 34877867

Group type: EXPERIMENTAL
Intervention: Nab-PTX, S-1, and sintilimab (8 cycles, Nab-PTX on days 1 and 8, S-1 on days 1 to 14, sintilimab on day 1, maintenance for up to 12 months)
Number of subjects: 0
Study: 34878173

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 1615

Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 1615

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 1615
Study: 34878437

Group type: EXPERIMENTAL
Intervention: Probiotics (five-strain probiotic capsules, 1.2 × 10^10 CFUs/d for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no probiotics)
Number of subjects: 20
Study: 34878624

Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg twice daily with estradiol 1 mg/norethindrone acetate 0.5 mg daily
Number of subjects: 2168
Study: 34878892

Group type: EXPERIMENTAL
Intervention: Imaging-guided adrenalectomy
Number of subjects: 231

Group type: COMPARATOR
Intervention: Adrenal vein sampling
Number of subjects: 231
Study: 34878898

Group type: EXPERIMENTAL
Intervention: Lead levels in quartile four (≥6.5 µg/dL)
Number of subjects: 2504

Group type: COMPARATOR
Intervention: Lead levels in quartile one (<3.4 µg/dL)
Number of subjects: 2504
Study: 34878959

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (QIV)
Number of subjects: 636
Study: 34878991

Group type: EXPERIMENTAL
Intervention: iCanManage smartphone-based interactive CRC self-management enhancement psychosocial program
Number of subjects: 5
Study: 34879143

Group type: EXPERIMENTAL
Intervention: Bougie
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Endotracheal tube with stylet
Number of subjects: 1102
Study: 34879299

Group type: EXPERIMENTAL
Intervention: Combined shear wave elastography (SWE) and strain elastography (SE)
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Routine B-mode breast ultrasound
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Combined SWE and SE
Number of subjects: 1288
Study: 34879394

Group type: EXPERIMENTAL
Intervention: Clotting factor concentrates (observed CVD incidence)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Severe hemophilia treated on demand
Number of subjects: 709

Group type: COMPARATOR
Intervention: Predicted CVD incidence based on QRISK2-2011 CVD risk model
Number of subjects: 709
Study: 34879833

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Neopterin
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Kynurenic acid (KA)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Neopterin (in combination with KA)
Number of subjects: 354
Study: 34879854

Group type: EXPERIMENTAL
Intervention: Assessment of placental biochemical and biophysical cardiovascular markers in the first and third trimesters of pregnancy.
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Maternal echocardiographic parameters assessed during pregnancy.
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Fetal cardiac function evaluated in the third trimester of pregnancy.
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Assessment of new cardiac biomarkers.
Number of subjects: 440
Study: 34879862

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post-tetanic count 1-5)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (tetanic count of four > 1)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Standard intra-abdominal pressure (≥10 mmHg)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Low intra-abdominal pressure (<10 mmHg)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 556
Study: 34879861

Group type: EXPERIMENTAL
Intervention: NIHSS extinction and inattention subtest
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: NIHSS visual field subtest
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: NIHSS extinction and inattention item
Number of subjects: 118
Study: 34879873

Group type: EXPERIMENTAL
Intervention: Exercising Together© (dyadic resistance training program)
Number of subjects: 10
Study: 34880013

Group type: EXPERIMENTAL
Intervention: Single infusion of autologous ex vivo expanded regulatory T cells (Treg)
Number of subjects: 10
Study: 34880087

Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) delivered over a 2-year period.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) with varying pulse amplitudes (20 to 80 µA).
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Detection thresholds estimated on a subset of electrodes.
Number of subjects: 1
Study: 34880117

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESIs) for sciatica
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Sacroiliac joint (SIJ) injections
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Facet interventions
Number of subjects: 346

Group type: COMPARATOR
Intervention: All groups (combined)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 346
Study: 34880620

Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation (NMES)
Number of subjects: 40
Study: 34880809

Group type: EXPERIMENTAL
Intervention: Home-Based Individual Cognitive Stimulation Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34881407

Group type: EXPERIMENTAL
Intervention: Emergency Rapid Intubation Teams (ERIT)
Number of subjects: 117
Study: 34881720

Group type: EXPERIMENTAL
Intervention: WhatsApp usage for COVID-19 content transmission
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: High volume of forwarded COVID-19 content
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Engagement with COVID-19 content in personal chats
Number of subjects: 151
Study: 34882037

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 1216
Study: 34882183

Group type: EXPERIMENTAL
Intervention: Bone-anchored annular closure device
Number of subjects: 554

Group type: COMPARATOR
Intervention: Lumbar microdiscectomy only (control group)
Number of subjects: 554
Study: 34882311

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 3406

Group type: COMPARATOR
Intervention: Non-selective NSAIDs
Number of subjects: 3406

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 3406
Study: 34882570

Group type: EXPERIMENTAL
Intervention: Intranasal racemic ketamine hydrochloride administered twice per week for 4 weeks (8 sessions)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intranasal racemic ketamine hydrochloride
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Number of subjects: 25
Study: 34882589

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (3 µg intramuscular doses, two doses 28 days apart)
Number of subjects: 3371

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine
Number of subjects: 3371
Study: 34882591

Group type: EXPERIMENTAL
Intervention: Damage-control surgery (DCS)
Number of subjects: 2174

Group type: COMPARATOR
Intervention: Conventional surgery (CS)
Number of subjects: 2174
Study: 34882631

Group type: EXPERIMENTAL
Intervention: Acupuncture (once a week for 10 weeks)
Number of subjects: 9
Study: 34882644

Group type: EXPERIMENTAL
Intervention: Biologics treatment
Number of subjects: 5938

Group type: EXPERIMENTAL
Intervention: Natural language processing and machine learning predictive model
Number of subjects: 5938
Study: 34882831

Group type: EXPERIMENTAL
Intervention: Once-weekly selinexor, bortezomib, and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard twice-weekly bortezomib and dexamethasone
Number of subjects: 0
Study: 34882989

Group type: EXPERIMENTAL
Intervention: Haemodynamic-guided management using the CardioMEMS HF System
Number of subjects: 100
Study: 34884196

Group type: EXPERIMENTAL
Intervention: C-reactive protein velocity (CRPv) measured as the difference of CRP 24 ± 8 h and CRP at hospital admission divided by the time (in h) that elapsed during the two examinations.
Number of subjects: 432
Study: 34886825

Group type: EXPERIMENTAL
Intervention: hsPDA group
Number of subjects: 123

Group type: COMPARATOR
Intervention: PDA group
Number of subjects: 123

Group type: COMPARATOR
Intervention: noPDA group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Renal oxygenation
Number of subjects: 123
Study: 34886885

Group type: EXPERIMENTAL
Intervention: TOFscan
Number of subjects: 35

Group type: COMPARATOR
Intervention: TOF-Watch SX
Number of subjects: 35
Study: 34886896

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily Examen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 100